Colloid Carcinoma of Pancreas in the Setting of Intraductal Papillary Mucinous Neoplasm (IPMN)

Jayakrishnan, Thejus; Pandya, Dhwani; Monga, Dulabh

doi:10.1007/s12029-019-00322-w

Cited by 4 publications

(3 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Most CC occurs in the context of IPMN, especially in close relation to intestinal type IPMN, as well as gastric type, pancreatic bile duct type and eosinophilic type [3,7] . Most studies have shown that CC has a better prognosis than other pancreatic cancers, with a 5-year survival rate of 28-55% compared with 5-12% for pancreatic cancers [2,8,9] . Currently, the main reasons are as follows: CC and IPMN usually rich in sticky protein 2 (MUC2), and contains no sticky protein 1 ((MUC1)),but PDAC express MUC1 strongly and lack of MUC2, MUC2 epithelial cells as a barrier to inhibit invasion of tumor cells to prevent further spread, which has a tumor suppressor activity, at the same time, the CC, mismatch repair gene mutation and microsatellite instability frequency is lower, so CC and IPMN malignant degree lower [10][11][12][13] , so there is even some lymph node metastasis is still alive and disease-free survival in 10 years' time [13] .…”

Section: Discussionmentioning

confidence: 99%

“…Colloid carcinoma(CC) is a variant type of Pancreatic ductal adenocarcinoma, often associated with Intraductal papillary mucinous neoplasm (IPMN), and is relatively rare. It accounts for about 1-3% of all pancreatic cancers [2] . With the further research on IPMN in recent years, the number of cases of IPMN developing into CC has increased signi cantly.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Colloid Carcinoma of the Pancreas: A Case Report

Wei

2021

Preprint

View full text Add to dashboard Cite

Background: Pancreatic colloid carcinoma is a rare pancreatic cancer, which is a subtype of pancreatic ductal adenocarcinoma. Case: a 71-year-old woman with a tumor of about 1.9x1.3cm in size located in the neck and body of the pancreas without invasion of surrounding organs. The patient underwent body and tail pancreatectomy, and the pathology revealed an intraductal papillary mucinous tumor of the pancreas with associated infiltrating colloid carcinoma. The patient recovered well after surgical treatment. Conclusion: Pancreatic colloid carcinoma is a malignant tumor, but it has a lower degree of malignancy and a better prognosis compared with pancreatic ductal adenocarcinoma. Currently, radical surgical resection is the main treatment principle.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Colloid Carcinoma of the Pancreas: A Case Report

Wei

2021

Preprint

View full text Add to dashboard Cite

show abstract

“…However, when they do progress, BD-PIMNs present with a tubular/ductal carcinoma histology, which, as mentioned above, has a very poor prognosis, similar to classic PDAC [28]. MD-IPMNs more often show intestinal and pancreaticobiliary histology, which tend to be high-grade lesions and are at increased risk of progression to invasive carcinoma [26,29,30]. Of note, intestinal IPMNs give rise to colloid carcinomas, while tubular carcinomas usually arise from gastric and pancreaticobiliary IPMNs [25,31].…”

Section: Definition Epidemiology and Classification Systemsmentioning

confidence: 96%

Intraductal Pancreatic Mucinous Neoplasms: A Tumor-Biology Based Approach for Risk Stratification

Nasca

Chiaravalli

Piro

et al. 2020

IJMS

View full text Add to dashboard Cite

Pancreatic ductal adenocarcinoma is one of the most lethal human cancers. Its precursor lesions include pancreatic intra-epithelial neoplasia, mucinous cystic neoplasm, and intraductal papillary mucinous neoplasm (IPMN). IPMNs usually present as an incidental finding at imaging in 2.6% of the population and, according to the degree of dysplasia, they are classified as low- or high-grade lesions. Since the risk of malignant transformation is not accurately predictable, the management of these lesions is based on morphological and clinical parameters, such as presence of mural nodule, main pancreatic duct dilation, presence of symptoms, or high-grade dysplasia. Although the main genetic alterations associated to IPMNs have been elucidated, they are still not helpful for disease risk stratification. The growing body of genomic and epigenomic studies along with the more recent development of organotypic cultures provide the opportunity to improve our understanding of the malignant transformation process, which will likely deliver biomarkers to help discriminate between low- and high-risk lesions. Recent insights on the topic are herein summarized.

show abstract